I edit this news page on Topix when no humans are available to help.
People just like you make BiCNU, Carmustine News on Topix better every day. If you're interested in becoming an editor, apply today!
Oct 20, 2009 | McGill University Newswire
International clinical trial for patients with brain tumours, co-ordinated at The Neuro
The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.
Related Topix: Medicine, Temodar, Temozolomide (generic), Oncology
Also on Topix
20 min ago | ABC
Bombs Kill 18 in Iraq, Wound Anbar Governor
28 min ago | LA Times
Afghan panel says U.S. strike killed 8 schoolboys
1 hr ago | NY Times
North Korea Said to Be Looting Heavy Equipment
2 hrs ago | ABC
China Vows to Cut Red Tape for Foreign Investors
3 hrs ago | ABC
Iranian Security Forces Intensify Crackdown
7 hrs ago | USA Today
GM offers dealers incentives on Pontiacs, Saturns
13 hrs ago | CBS
Poll: Health Care Vote May be Bad News for Ben Nelson in ...
14 hrs ago | CBS
Mexico City Enacts Region's 1st Gay Marriage Law
16 hrs ago | NY Times
Freakonomics meets Pirates of the Caribbean
17 hrs ago | CBS
Haqqani Network Challenges US-Pakistan Relations
Recent activity of our hottest topics
Bioinformatics
Northampton, MA
Baxley, GA
Saltville, VA
Delano, CA
Junction City, KS
Lenoir, NC
El Dorado, AR
New Year's Day/Eve
Natchitoches, LA
Clarkton, MO
Florida Gators NCAA F...
|
Your town, your news |
Explore More Topix |
About Topix |
Reach local customers. Engage a specific demographic. Maximize business-to-business opportunities. Topix can deliver your message.
|
Copyright ©2009 Topix LLC

• Flag inappropriate postPost has been flagged for review
• Priority Review request ($19.99)
• Cancel
Change location for your local news
Current location: Cambodia
International users, click here to set your location.
What is Topix?
Topix is the largest news community on the web.
We take news from over 60,000 sources and categorize those stories to over 40,600 locations and 450,000 topics.
Topix breaks the mold of traditional news sites by allowing our users to edit the news. We've built a suite of editing tools, so Topix users can make sure all the stories that matter get the attention they deserve.
The best part? You can comment on everything. Every story, every poll, every user-submitted photo.
Jump in, find a topic and start talking!
By the way, if you're interested in learning more about Topix, visit our blog.
